Neal D. Shore

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

5in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 5 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

10.1158/1078-0432.23626885

Top 100%

0DataRank

Top 100%0 citations

Sumit K. Subudhi, Christopher Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason Hafron +6 more

Papers

Driven by 18 papers — median percentile 0. Top paper: “Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry”.

Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry

Prostate Cancer and Prostatic Diseases(2020)10.1038/s41391-020-0213-7

N/A

4.8DataRank · unranked

145 citations

Andrew J. Armstrong, Chiledum Ahaghotu, David G. McLeod, Matthew R. Cooperberg, David F. Penson +17 more

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

The Lancet(2024)10.1016/s0140-6736(24)01653-2

N/A

4.3DataRank · unranked

287 citations

Daniel Castellano, Ken Herrmann, Johann S. De Bono, Neal D. Shore, Kim N. +18 more

Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial

The Journal of Urology(2024)10.1097/ju.0000000000004020

N/A

1.6DataRank · unranked

77 citations

Stephen A. Boorjian, Mehrdad Alemozaffar, Badrinath R. Konety, Neal D. Shore, Leonard G. Gomella +35 more

Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer

Annals of Oncology(2025)10.1016/j.annonc.2025.07.003

N/A

0.663DataRank · unranked

31 citations

K.N. Chi, Neal D. Shore, Ken Herrmann, Johann S. De Bono, Daniel Castellano +88 more

Advances in the understanding of cancer immunotherapy

BJU International(2015)10.1111/bju.12692

N/A

0.546DataRank · unranked

37 citations

Neal D. Shore

A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum‐resistant metastatic urothelial cancer

Cancer(2020)10.1002/cncr.33067

N/A

0.538DataRank · unranked

35 citations

Michael R. Harrison, Peter H. O’Donnell, Ajjai Alva, Noah M. Hahn, Leonard J. Appleman +17 more

Expert Perspectives on Controversies in Castration-Sensitive Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 1

JU Open Plus(2024)10.1097/ju9.0000000000000137

N/A

0.457DataRank · unranked

8 citations

Alan H. Bryce, Maha Hussain, Neeraj Agarwal, Himisha Beltran, Matthew R. Cooperberg +33 more

ARCHES 5-year Survival with Enzalutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients

European Urology(2026)10.1016/j.eururo.2025.12.021

N/A

0.241DataRank · unranked

4 citations

Daniel P. Petrylak, Neal D. Shore, Russell Z. Szmulewitz, Jeffrey Holzbeierlein, Arnauld Villers +11 more

Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery

Cancer Prevention Research(2024)10.1158/1940-6207.capr-24-0194

N/A

0.220DataRank · unranked

2 citations

Howard H. Bailey, Taja Ložar, Natalie Schmitz, Heather Green, Cameron O. Scarlett +15 more

VAX014 for instillation in subjects with nonmuscle-invasive bladder cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.6_suppl.488

N/A

0DataRank · unranked

5 citations

Lawrence I. Karsh, Michael A. O’Donnell, Neal D. Shore, Yair Lotan, Shingo Tsuji +2 more

Expert Perspectives on Controversies in Metastatic Castration-Resistant Prostate Cancer Management: Narrative Review and Report of the First US Prostate Cancer Conference Part 2

JU Open Plus(2024)10.1097/ju9.0000000000000138

N/A

0DataRank · unranked

3 citations

E. David Crawford, Neeraj Agarwal, Maha Hussain, Himisha Beltran, Matthew R. Cooperberg +33 more

Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps5117

N/A

0DataRank · unranked

0 citations

Jose W. Avitia, James L. Bailen, Luke T. Nordquist, William J. Richardson, Cody J. Peer +8 more

Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer

Urologic Oncology Seminars and Original Investigations(2020)10.1016/j.urolonc.2020.08.003

N/A

0DataRank · unranked

41 citations

Neal D. Shore, Diane Cope, Andrea McNatty, Javid J. Moslehi, Leonard G. Gomella +2 more

Supplementary Fig. 3 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

10.1158/1078-0432.23626876

N/A

0DataRank · unranked

0 citations

Sumit K. Subudhi, Christopher Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason Hafron +6 more

Supplementary Data 1 from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

10.1158/1078-0432.23626885

Top 100%

0DataRank

Top 100%0 citations

Sumit K. Subudhi, Christopher Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason Hafron +6 more

Data from Combination Treatment with Sipuleucel-T and Abiraterone Acetate or Enzalutamide for Metastatic Castration-Resistant Prostate Cancer: STAMP and STRIDE Trials

10.1158/1078-0432.c.6666732.v2

N/A

0DataRank · unranked

0 citations

Sumit K. Subudhi, Christopher Pieczonka, Lawrence I. Karsh, David I. Quinn, Jason Hafron +6 more

An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer

International Journal of Radiation Oncology*Biology*Physics(2021)10.1016/j.ijrobp.2021.12.005

N/A

0DataRank · unranked

12 citations

Nicholas G. Zaorsky, H.P. Bagshaw, Alejandro Berlín, Alison Tree, Sandra Turner +21 more

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer

Bladder Cancer(2023)10.3233/blc-230056

N/A

0DataRank · unranked

8 citations

Noah M. Hahn, Seth P. Lerner, Jaleh Fallah, Sundeep Agrawal, Ashish M. Kamat +33 more

Neal D. Shore

Indexed papers

Top data-sharing exemplar

Papers